Evotec has achieved a milestone in its research alliance with Boehringer Ingelheim, triggering a payment of $3.3 million. The milestone was achieved for the identification and selection of a compound to be advanced into extended profiling prior to pre-clinical development within an oncology programme. This was the fourth milestone achieved in 2011 and represents a total of $14.5 million of milestones achieved within that year. Dr Mario Polywka, chief operating officer of Evotec, commented, &#82...